Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance).
Journal: The Journal of clinical investigation
Published: August 04, 2026
Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.
Journal: JCO oncology advances
Published: May 18, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.
Journal: Journal for immunotherapy of cancer
Published: April 20, 2026
Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?
Journal: The Lancet. Oncology
Published: October 13, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: September 05, 2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
Journal: Future oncology (London, England)
Published: June 27, 2025
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.
Journal: NPJ breast cancer
Published: October 04, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Journal: Cancer
Published: August 07, 2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.
Journal: NPJ precision oncology
Published: November 07, 2022
Reply to the Letter to the Editor 'Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer' by A. Okines and N. Turner.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
Journal: NAR cancer
Published: March 03, 2022
Last Updated: 09/26/2026